Sierra Oncology LLC clinical trials
Acquired by GlaxoSmithKline, Jul 1, 2022 · source ↗
The registry lists 19 studies whose lead sponsor is Sierra Oncology LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 1, 2023.
- 19studies on the registry
- 0open to participants now
Before and after it joined GlaxoSmithKline
- First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- 19
- First submitted after Sierra Oncology LLC became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Sierra Oncology LLC’s studies test, most studies first; none is open now — 5 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 19 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 09
- 10
- 11
- 12
- 13
- 714
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Sierra Oncology LLC - a GSK company19 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 19 of 19. All GlaxoSmithKline studies →
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)CompletedNCT02226965Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)TerminatedNCT02378038Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01733238Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer SubjectsCompletedNCT02797977Phase 1/2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- A Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerCompletedNCT02797964Phase 1/2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedNCT01969838Phase 3
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- A Study of PNT2258 in Patients With Advanced Solid TumorsCompletedNCT01191775Phase 1
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT01236638Phase 2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02244489Phase 1
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT00935987Phase 1/2
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
Sponsor listed in the registry: Sierra Oncology LLC - a GSK company · First submitted before Sierra Oncology LLC became part of GlaxoSmithKline